Journal Mobile Options
Table of Contents
Vol. 97, No. 4, 2004
Issue release date: August 2004
Section title: Original Paper
Nephron Clin Pract 2004;97:c154–c159
(DOI:10.1159/000079175)

Prolonged Treatment with Low-Dose Intravenous Pulse Cyclophosphamide May Reduce Rate of Relapse in ANCA-Associated Vasculitis

Dhaygude A. · Griffith M. · Cairns T. · McLean A. · Palmer A. · Taube D.
Renal Unit, St. Mary’s Hospital, London, UK

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 1/16/2004
Accepted: 4/19/2004
Published online: 11/17/2004

Number of Print Pages: 1
Number of Figures: 3
Number of Tables: 1

ISSN: (Print)
eISSN: 1660-2110 (Online)

For additional information: http://www.karger.com/NEC

Abstract

Background: Cyclophosphamide has transformed the outcome of ANCA-associated vasculitis, but it is highly toxic. Recent studies have suggested that pulsed intravenous cyclophosphamide (pCyc) is an effective alternative with less complications, but may lead to an increased rate of relapse. However, these studies used relatively short courses of treatment with cyclophosphamide. In this study we used a prolonged course of low-dose intravenous cyclophosphamide for 18–24 months for ANCA-associated vasculitis, evaluated the effectiveness of pCyc and analysed the outcome of a prolonged treatment on the rate of relapse. Methods: A retrospective analysis of all the patients treated with pCyc from 1995 to 2002 was performed. Results: Thirty-seven patients were followed for an average of 38 months. Thirty-four of 37 patients (91.9%) achieved complete remission at 3 months. Eight (21%) episodes of relapse occurred in 7 patients. The cyclophosphamide was well tolerated with a low rate of infections (18.9%) and 1 death (2.7%) due to sepsis whilst on cyclophosphamide. Conclusion: In this study, pCyc was effective in achieving rapid remission and had a low complication rate. If prolonged, this treatment may reduce the rate of relapse.


  

Author Contacts

Ajay Dhaygude
Renal Unit, Mint Wing
St. Mary’s Hospital
London W2 1NY (UK)
Tel. +44 207 886 6819, Fax +44 207 886 6901, E-Mail adhaygude@yahoo.com

  

Article Information

Received: January 16, 2004
Accepted: April 19, 2004
Number of Print Pages : 6
Number of Figures : 3, Number of Tables : 1, Number of References : 22

  

Publication Details

Nephron Clinical Practice
Founded 1964 by G. Richet and G.E. Schreiner

Vol. 97, No. 4, Year 2004 (Cover Date: August 2004)

Journal Editor: S.H. Powis, London
ISSN: 0028–2766 (print), 1660–2110 (Online)

For additional information: http://www.karger.com/nec


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 1/16/2004
Accepted: 4/19/2004
Published online: 11/17/2004

Number of Print Pages: 1
Number of Figures: 3
Number of Tables: 1

ISSN: (Print)
eISSN: 1660-2110 (Online)

For additional information: http://www.karger.com/NEC


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.